Amcor plc (ASX: AMC) — Investment Research Report

3-Year / 5-Year Price Scenarios

Base EPS: $1.1 — Approximate AUD normalised EPS derived from FY2025 adjusted EPS of US$0.712 and the reported Q3 FY2026 adjusted EPS run-rate, translated at an indicative A$1.55/US$; the translation and normalisation are analyst calculations, not company guidance.

0. Information Richness & AI Limitations

Grade A for disclosure, not certainty. Amcor publishes detailed annual and quarterly results, segment information, non-GAAP reconciliations and dividend announcements. The current investor calendar showed FY2026 full-year results scheduled for 12 August 2026, so this report uses the published FY2025 annual release and Q3 FY2026 release available by the 31 July 2026 cutoff. The price is independently verified for 31 July. Confidence is higher on reported history and business description than on five-year valuation, which depends on merger synergies, currency, leverage and packaging volumes.

1. Data & Cross-Validation

The verified ASX/CDI price was A$64.66 on 31 July 2026. ASX header market capitalisation was approximately A$30.293B; dividing by price implies approximately 468.6M equivalent shares and reconciles by construction. Yahoo's chart API independently returned the same A$64.66 close; the ASX header was the independent transport fallback used during research.

USD reported financials: FY2025 net sales were US$15.009B, GAAP net income US$511M, adjusted EPS US$0.712 and adjusted free cash flow US$926M (Amcor FY2025 press-release PDF, 14 August 2025). Q3 FY2026 net sales were US$5.914B, GAAP net income US$278M and adjusted EPS US$0.96; nine-month net sales were US$17.108B, GAAP net income US$717M and adjusted EPS US$2.79 (Amcor Q3 release, 6 May 2026). The Q3 release and Amcor's dividend page both reported a US$0.65 quarterly dividend, with A$0.91 CDI equivalent.

The financial-year comparison is not a like-for-like growth series because the Berry Global combination changed the group perimeter and creates synergy, financing and integration effects. The report therefore prioritises cash flow, margin recovery and deleveraging over headline revenue growth.

2. Business Essence — Duan Yongping

One line: Amcor converts films, resins, paper and other materials into packaging used by food, beverage, healthcare, personal-care and industrial customers worldwide.

Packaging is an essential but competitive intermediate product. Customer qualification, tooling, regulatory compliance, quality assurance and supply reliability create repeat business and moderate switching costs, especially in healthcare and technically demanding formats. The economics are not subscription-like: volumes follow consumer demand, contracts can reset for materials and customers remain price-conscious. Operating leverage appears when volumes recover, procurement improves and the Berry integration delivers synergies, but debt service and resin, labour, energy and freight inflation limit the upside.

3. Moat — Buffett

Amcor's moat is scale plus qualification, not a consumer brand. A global footprint supports procurement, technical know-how, product breadth and supply continuity; regulated healthcare packaging and complex customer specifications increase switching friction. Physical plants, tooling, quality systems and customer approvals take time and capital to replicate. Network effects are weak, and basic films or containers are contestable commodities.

The moat is stable to modestly widening where the combined group can cross-sell and spread innovation and compliance costs, but merger complexity is a real counterweight. Sustainable-material requirements can create opportunity for a technically capable supplier, while lightweighting, reuse and recycling can reduce some legacy volume.

4. Reverse Thinking & Risks — Munger

Invert the thesis: an apparently defensive packaging company can lose value through a combination of modest organic growth, high debt, aggressive synergy assumptions and multiple compression. Historical analogies are global converters and materials manufacturers that earned adequate but cyclical returns, not software-like economics. Disconfirming evidence would be sustained positive organic volume, clean synergy delivery, falling net leverage and free cash flow exceeding integration needs.

5. Management — Duan Yongping + Buffett

Management's central test is execution of the Berry combination: deliver synergies, preserve customer service, reduce leverage and maintain disciplined capital spending. The FY2025 release showed US$926M of adjusted free cash flow and a continuing dividend, while the Q3 FY2026 release updated guidance after the integration had begun. That is useful evidence of operating cash generation, but it does not yet prove the full deal thesis.

Capital allocation should be judged by deleveraging before buybacks, transparent non-GAAP reconciliation and a dividend covered by durable free cash flow. The business should remain competitive without a heroic CEO because its advantages are institutional—plants, approvals, technical teams and customer relationships—but poor integration governance could destroy value.

6. Industry & Civilizational Trend — Li Lu

Packaging is infrastructure for modern consumption and healthcare. Population, food safety, convenience, medical products and emerging-market consumption support long-run demand, but the total addressable market is constrained by mature-market volumes, material efficiency and regulation. Amcor sits between chemical/material suppliers and branded consumer and healthcare companies, where scale and compliance matter but customers retain bargaining power.

The long-term technological direction is toward lightweighting, recycled content, recyclability, reuse and lower-carbon production. This can favour a large supplier able to invest in innovation and compliance, but can also require capex and make some formats obsolete. Amcor is more likely to be a durable compounder of modest returns than a civilization-changing monopoly.

7. Valuation & Scenarios — Buffett + Duan

The current price is approximately 58.8x the analyst-normalised A$1.10 EPS base, so valuation is demanding for a leveraged, cyclical packaging manufacturer even after allowing for merger synergies. The base EPS is a calculation from reported USD adjusted EPS and an indicative exchange rate, not management guidance. The scenarios deliberately combine EPS growth and exit P/E rather than pretending to know a precise intrinsic value.

3-year: Bull A$95 at 25% probability, base A$63 at 50%, bear A$39 at 25%; probability-weighted target A$65, approximately +0.5% before dividends. 5-year: Bull A$125 at 25%, base A$70 at 50%, bear A$35 at 25%; weighted target A$75, approximately +16.0% before dividends. The main uncertainty is whether synergies and deleveraging justify a sustained multiple; currency translation, packaging volumes, interest rates and capital allocation can move outcomes materially.

8. Decision Memo

Decision: watchlist / no new position at current price. A staged entry around A$50–58 would provide more margin for execution risk. Holders can retain exposure while free cash flow, customer retention and leverage improve. Sell or reassess if synergies are repeatedly cut, leverage rises, organic volumes remain negative or the dividend becomes debt-funded. Add when deleveraging is visible and the price offers a risk-adjusted return above the base case.

Four-Master Commentary

Buffett (analytical simulation, not a real quotation): "Packaging is necessary and scale matters, but I want a durable return on capital after debt and maintenance capex—not just a large pro-forma synergy number."

Munger (analytical simulation, not a real quotation): "Invert it: the combination of leverage, customer bargaining power and a full price can make an ordinary outcome a poor investment."

Duan Yongping (analytical simulation, not a real quotation): "The customer relationships and qualified production are useful assets; wait for a price where execution does not have to be perfect."

Li Lu (analytical simulation, not a real quotation): "Packaging follows the physical economy and healthcare, so it should endure, but sustainability changes which formats and assets win over decades."